期刊
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
卷 43, 期 1, 页码 34-41出版社
SPRINGER
DOI: 10.1007/s00259-015-3188-1
关键词
Prostate cancer; Ga-68-PSMA ligand PET/CT; Radiotherapy planning; Individualized radiotherapy
资金
- Klaus-Tschira-Stiftung [00.198.2012]
Purpose Radiotherapy is the main therapeutic approach besides surgery of localized prostate cancer. It relies on risk stratification and exact staging. This report analyses the potential of [Ga-68]Glu-urea-Lys(Ahx)-HBED-CC (Ga-68-PSMA-11), a new positron emission tomography (PET) tracer targeting prostate-specific membrane antigen (PSMA) for prostate cancer staging and individualized radiotherapy planning. Methods A cohort of 57 patients with prostate cancer scanned with Ga-68-PSMA-11 PET/CT for radiotherapy planning was retrospectively reviewed; 15 patients were at initial diagnosis and 42 patients at time of biochemical recurrence. Staging results of conventional imaging, including bone scintigraphy, CT or MRI, were compared with Ga-68-PSMA ligand PET/CT results and the influence on radiotherapeutic management was quantified. Results Ga-68-PSMA ligand PET/CT had a dramatic impact on radiotherapy application in the presented cohort. In 50.8 % of the cases therapy was changed. Conclusion The presented imaging technique of Ga-68-PSMA PET/CT could be a key technology for individualized radiotherapy management in prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据